Alveus Therapeutics is a startup based in the United States, most recent round Series A, 1 tracked investor.
Alveus Therapeutics is a startup founded in 2025 based in the United States. Its most recent tracked round is Series A. Brouky records 1 investor associated with the company.
Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, with a focus on sustained efficacy and improved tolerability. They are advancing a pipeline of peptide- and protein-based metabolic therapeutics, including their lead asset ALV-100 in Phase 2 clinical development.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.